The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Gut

Volumn 64, Issue 10, 2015, Pages 1539-1545

  Casteele, Niels Vande ^a,b,c   Khanna, Reena ^c   Levesque, Barrett G ^b,c   Stitt, Larry ^c   Zou, G Y ^c   Singh, Sharat ^d   Lockton, Steve ^d   Hauenstein, Scott ^d   Ohrmund, Linda ^d   Greenberg, Gordon R ^e   Rutgeerts, Paul J ^a   Gils, Ann ^a   Sandborn, William J ^b   Vermeire, Séverine ^a   Feagan, Brian G ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d Prometheus Laboratories Inc ^*  (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; INFLIXIMAB; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REMISSION; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; IMMUNOLOGY; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, MONOCLONAL; BIOMARKERS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84941330342     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307883     Document Type: Article

References (37)

1. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
2. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18.
3. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.
4. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit 2013;35:530-8.
5. Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Therap 2012;36:765-71.
6. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-64.
7. Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17.
8. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7.
9. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
10. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
11. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013;7:736-43.
12. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
13. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014;12:1474-1481.e2.
14. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-4.
15. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013;19:2568-76.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
17. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014;63:1721-7.
18. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27.
19. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
20. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:378.
21. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55.
22. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-9.
23. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
24. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-8.
25. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014;39:1126-35.
26. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease. Clin Gastroenterol Hepatol. Published Online First: 24 July 2014. doi:10.1016/j.cgh.2014.07.027
27. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88.
28. Obuchowski NA Nonparametric analysis of clustered ROC curve data. Biometrics 1997;53:567-78.
29. Rehlaender BN, Cho MJ. Antibodies as carrier proteins. Pharm Res 1998;15:1652-6.
30. Brandse JF, van der Kleij D, Wolbink G-J, et al. 786 the pharmacokinetics of infliximab induction therapy in patients with moderate to severe ulcerative colitis. Gastroenterology 2014;146:S-134.
31. Yamada A, Sono K, Hosoe N, et al. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010;16:1898-904.
32. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
33. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654-66.
34. Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361-8.
35. Vande Casteele N, Compernolle G, Ballet V, et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis 2012;6:S6.
36. Vande Casteele N, Gils A, Ballet V, et al. OP001 Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol J 2013;1:A1.
37. Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011;9:421-7.